PMV Pharmaceuticals (PMVP) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Entity File Number	001-39539
Entity Registrant Name	PMV PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-3218129
Entity Address, Address Line One	8 Clarke Drive
Entity Address, Address Line Two	Suite 3
Entity Address, City or Town	Cranbury
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08512
City Area Code	609
Local Phone Number	642-6670
Title of 12(b) Security	Common stock, par value $0.00001
Trading Symbol	PMVP
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		45,380,354
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001699382
Amendment Flag	false

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 176,641	$ 361,422
Restricted cash	822
Marketable securities, current	131,010
Prepaid expenses and other current assets	5,082	3,339
Total current assets	313,555	364,761
Property and equipment, net	1,394	569
Marketable securities, noncurrent	18,601
Right-of-use assets, operating leases	10,410
Other assets	218	201
Total assets	344,178	365,531
Current liabilities:
Accounts payable	1,278	1,607
Accrued expenses	6,740	4,803
Operating lease liability, current	545
Total current liabilities	8,563	6,410
Operating lease liability, noncurrent	10,667
Total liabilities	19,230	6,410
Stockholders’ equity:
Preferred stock, $0.00001 par value, 5,000,000 shares authorized at September 30, 2021 (unaudited) and December 31, 2020. No shares issued or outstanding at September 30, 2021 (unaudited) and December 31, 2020.
Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 45,352,207 and 44,777,818 shares issued and outstanding at September 30, 2021 (unaudited) and December 31, 2020, respectively.
Additional paid-in capital	474,301	469,001
Accumulated deficit	(149,367)	(109,880)
Accumulated other comprehensive income	14
Total stockholders’ equity	324,948	359,121
Total liabilities and stockholders’ equity	$ 344,178	$ 365,531

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	45,352,207	44,777,818
Common stock, shares outstanding	45,352,207	44,777,818

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 9,162	$ 5,992	$ 24,326	$ 17,752
General and administrative	5,935	2,709	15,495	6,689
Total operating expenses	15,097	8,701	39,821	24,441
Loss from operations	(15,097)	(8,701)	(39,821)	(24,441)
Other income (expense):
Interest income, net	102	40	343	603
Other income (expense)	3	(100)	14	(143)
Total other income (expense)	105	(60)	357	460
Loss before provision for income taxes	(14,992)	(8,761)	(39,464)	(23,981)
Provision for income taxes	19	3	23	5
Net loss	(15,011)	(8,764)	(39,487)	(23,986)
Unrealized gains (loss) on marketable securities, net of tax	7	(5)	14	3
Comprehensive loss	$ (15,004)	$ (8,769)	$ (39,473)	$ (23,983)
Net loss per share -- basic and diluted	$ (0.33)	$ (1.46)	$ (0.88)	$ (5.93)
Weighted-average common shares outstanding	45,295,232	6,022,457	45,052,100	4,045,527

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Series D Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Balance at Dec. 31, 2019	$ (70,474)				$ 4,969	$ (3)	$ (75,440)
Balance, Shares at Dec. 31, 2019		22,866,246
Balance at Dec. 31, 2019		$ 168,933
Balance, Shares at Dec. 31, 2019				3,046,200
Stock-based compensation expense	296				296
Net loss	(7,255)						(7,255)
Unrealized gain (loss) on available for sale investments	(80)					(80)
Balance at Mar. 31, 2020	(77,513)				5,265	(83)	(82,695)
Balance, Shares at Mar. 31, 2020		22,866,246
Balance at Mar. 31, 2020		$ 168,933
Balance, Shares at Mar. 31, 2020				3,046,200
Balance at Dec. 31, 2019	(70,474)				4,969	(3)	(75,440)
Balance, Shares at Dec. 31, 2019		22,866,246
Balance at Dec. 31, 2019		$ 168,933
Balance, Shares at Dec. 31, 2019				3,046,200
Net loss	(23,986)
Balance at Sep. 30, 2020	368,970				468,396		(99,426)
Balance, Shares at Sep. 30, 2020				44,773,748
Balance at Mar. 31, 2020	(77,513)				5,265	(83)	(82,695)
Balance, Shares at Mar. 31, 2020		22,866,246
Balance at Mar. 31, 2020		$ 168,933
Balance, Shares at Mar. 31, 2020				3,046,200
Stock-based compensation expense	383				383
Net loss	(7,967)						(7,967)
Unrealized gain (loss) on available for sale investments	88					88
Balance at Jun. 30, 2020	(85,009)				5,648	5	(90,662)
Balance, Shares at Jun. 30, 2020		22,866,246
Balance at Jun. 30, 2020		$ 168,933
Balance, Shares at Jun. 30, 2020				3,046,200
Issuance of convertible preferred stock			$ 69,790
Issuance of convertible preferred stock, Shares			5,321,864
Conversion of convertible preferred stock to common stock	$ (238,723)
Conversion of convertible preferred stock to common stock, Shares	(28,188,110)
Conversion of convertible preferred stock to common stock	$ 238,723				238,723
Conversion of convertible preferred stock to common stock, Shares				28,188,110
Exercise of warrants	194				194
Exercise of warrants, Shares				9,688
Issuance of common stock, net of issuance costs	223,161				223,161
Issuance of common stock, net of issuance costs, Shares				13,529,750
Stock-based compensation expense	670				670
Net loss	(8,764)						(8,764)
Unrealized gain (loss) on available for sale investments	(5)					(5)
Balance at Sep. 30, 2020	368,970				468,396		(99,426)
Balance, Shares at Sep. 30, 2020				44,773,748
Balance at Dec. 31, 2020	359,121				469,001		(109,880)
Balance, Shares at Dec. 31, 2020				44,777,818
Exercise of stock options and common stock issued under the 2020 ESPP	162				162
Exercise of stock options and common stock issued under the 2020 ESPP, Shares				103,351
Stock-based compensation expense	627				627
Net loss	(11,602)						(11,602)
Unrealized gain (loss) on available for sale investments	(13)					(13)
Balance at Mar. 31, 2021	348,295				469,790	(13)	(121,482)
Balance, Shares at Mar. 31, 2021				44,881,169
Balance at Dec. 31, 2020	359,121				469,001		(109,880)
Balance, Shares at Dec. 31, 2020				44,777,818
Net loss	(39,487)
Balance at Sep. 30, 2021	324,948				474,301	14	(149,367)
Balance, Shares at Sep. 30, 2021				45,352,207
Balance at Mar. 31, 2021	348,295				469,790	(13)	(121,482)
Balance, Shares at Mar. 31, 2021				44,881,169
Exercise of stock options and common stock issued under the 2020 ESPP	1,256				1,256
Exercise of stock options and common stock issued under the 2020 ESPP, Shares				332,398
Stock-based compensation expense	1,150				1,150
Net loss	(12,874)						(12,874)
Unrealized gain (loss) on available for sale investments	20					20
Balance at Jun. 30, 2021	337,847				472,196	7	(134,356)
Balance, Shares at Jun. 30, 2021				45,213,567
Exercise of stock options and common stock issued under the 2020 ESPP	309				309
Exercise of stock options and common stock issued under the 2020 ESPP, Shares				138,640
Stock-based compensation expense	1,796				1,796
Net loss	(15,011)						(15,011)
Unrealized gain (loss) on available for sale investments	7					7
Balance at Sep. 30, 2021	$ 324,948				$ 474,301	$ 14	$ (149,367)
Balance, Shares at Sep. 30, 2021				45,352,207

Condensed Statements of Conve_2

Condensed Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Sep. 30, 2020USD ($)
Common Stock
Issuance costs	$ 20,374
Series D Convertible Preferred Stock
Issuance costs	$ 210

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (39,487,000)	$ (23,986,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	3,573,000	1,349,000
Depreciation	230,000	257,000
Amortization of premiums on marketable securities	459,000	152,000
Non-cash lease expense	644,000
Other	(17,000)	144,000
Change in operating assets and liabilities:
Prepaid expenses and other assets	(1,743,000)	85,000
Accounts payable	(385,000)	(2,825,000)
Accrued expenses	2,183,000	2,397,000
Net cash used in operating activities	(34,543,000)	(22,427,000)
Cash flows from investing activities:
Purchase of property and equipment	(1,087,000)	(91,000)
Purchase of marketable securities	(235,167,000)	(14,512,000)
Maturities of marketable securities	85,111,000	42,571,000
Net cash (used in) provided by investing activities	(151,143,000)	27,968,000
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net		69,790,000
Proceeds from the issuance of common stock, net		224,541,000
Proceeds from exercise of stock options	1,727,000
Net cash provided by financing activities	1,727,000	294,331,000
Net (decrease) increase in cash, cash equivalents, and restricted cash	(183,959,000)	299,872,000
Cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash - beginning of period	361,422,000	73,278,000
Cash, cash equivalents, and restricted cash - end of period	177,463,000	373,150,000
Supplemental disclosures of noncash investing activities
Lease incentives used for leasehold improvements	88,000
Conversion of convertible preferred stock to common stock		238,723,000
Conversion of warrant liability to common stock		194,000
Unpaid offering costs		1,380,000
Supplemental disclosures of cash flow information
Cash paid for income tax	$ 23,000	$ 5,000

Formation and Business of the C

Formation and Business of the Company	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Formation and Business of the Company	1. Formation and Business of the Company Organization and Liquidity PMV Pharmaceuticals, Inc. (the “Company”) was incorporated in the state of Delaware in March 2013. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities and raising capital. The Company is a clinical-stage oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies designed to target p53 mutations. The Company’s headquarters are currently located in Cranbury, New Jersey. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. On September 25, 2020, the Company completed an initial public offering (the “IPO”) of 13,529,750 shares of common stock, at a public offering price of $18.00 per share including the exercise in full by the underwriters of their option to purchase up to 1,764,750 additional shares of commons stock, for aggregate gross proceeds of $243,536 and its shares started trading on The Nasdaq Global Select Market under the ticker symbol “PMVP.” The Company received $223,161 in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company. In connection with the closing of the IPO, all of the Company’s outstanding shares of convertible preferred stock outstanding at the time of the IPO automatically converted into 28,188,110 shares of common stock. On September 18, 2020, the Company amended its certificate of incorporation to effect a 5.2651-for-1 reverse stock split of its issued and outstanding common and convertible preferred stock. The accompanying unaudited condensed financial statements and related notes give retroactive effect to the reverse stock split for all periods presented. The Company has incurred net losses and negative cash flows from operations since its inception. During the three and nine months ended September 30, 2021, the Company incurred a net loss of $15,011 and $39,487, respectively. For the nine months ended September 30, 2021, the Company used $34,543 of cash for operations. At September 30, 2021, the Company had an accumulated deficit of $149,367. Cash, cash equivalents, and restricted cash at September 30, 2021 were $177,463. Short and long term marketable securities totaled $149,611 at September 30, 2021. Management expects to incur substantial additional operating losses for the next several years and will need to obtain additional debt or equity financings in order to complete development of its products, obtain regulatory approvals, launch and commercialize its products and continue research and development programs. The Company believes it has adequate cash and cash equivalents to operate for at least the next twelve months from the date of issuance of these unaudited condensed financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 3, 2021. Since the date of those financial statements, there have been no changes to its significant accounting policies except as noted below. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The condensed balance sheet as of September 30, 2021, the condensed statements of operations and comprehensive loss, and condensed statements of convertible preferred stock and stockholders’ (deficit) equity for the three and nine months ended September 30, 2021 and 2020, and the condensed statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for any interim period are not necessarily indicative of results for the year ending December 31, 202 1 or for any other subsequent interim period . The condensed balance sheet at December 31, 2020 has been derived from our audited financial statements . Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates. Reverse Stock Split In September 2020, the Company’s board of directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to affect a 5.2651-for-1 reverse stock split of the Company’s common stock and convertible preferred stock, which was effected on September 18, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these unaudited condensed financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Cash, Cash Equivalents and Marketable Securities Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. As of September 30, 2021, the company’s long-term marketable debt securities have maturity dates no more than 2 years. The Company’s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders’ deficit. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security. For the three months ended September 30, 2021 and 2020, the Company recorded $127 and $6 of amortization, respectively. For the nine months ended September 30, 2021 and 2020, the Company recorded $459 and $152 of amortization, respectively. Restricted cash as of September 30, 2021 included a $822 deposit at the Company’s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets. Comprehensive Loss The Company presents comprehensive loss in a single statement within its financial statements. Other comprehensive loss consists of unrealized gains and losses on marketable securities, net of tax. Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (“ROU”) assets and operating lease liabilities at the lease commencement date, and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company’s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company’s only existing leases are for office and laboratory space. The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company’s share of the lessor’s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Neither of the Company’s leases contain residual value guarantees. The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Recently Issued and Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-02, Leases The right-of-use lease liability for operating leases is based on the net present value of future minimum lease payments. Additionally, the right-of-use asset for operating leases is based on the lease liability adjusted for the reclassification of certain balance sheet amounts such as the long term portion of straight line rent liability and deferred lease incentives. The Company adopted the standard effective January 1, 2021 using the modified retrospective transition method. Upon adoption, the Company applied the package of practical expedients that allows an entity to not reassess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases and (iii) initial direct costs for any expired or existing leases. The Company elected the practical expedient not to apply the recognition requirements to short-term leases, defined as a lease that at the commencement date has a lease term of 12 months or less that does not include a purchase option to purchase the underlying asset that the Company is reasonably certain to exercise. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. As the Company enters into new leases, it will continue to evaluate this accounting policy for any new classes of underlying assets. Upon adoption, the Company recorded ROU assets of $970 and lease liabilities of $1,129. The standard did not have a material impact on the statement of operations or statement of cash flows. In December 2019, the FASB issued ASU 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company adopted this standard as of January 1, 2021. The adoption did not have a material impact on the Company’s financial statements. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company’s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired. The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals. Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company. In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a “Public Health Emergency of International Concern,” which continues to spread throughout the world . The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. The Company continues to monitor the impact of the COVID-19 outbreak closely. The full extent to which the COVID-19 outbreak will impact its operations or financial results remains uncertain.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	3. Fair Value Measurements The Company’s financial assets consist of money market funds, U.S. government debt securities and corporate debt securities. The following tables show the Company’s cash equivalents and available-for-sale securities’ carrying amounts and fair values at September 30, 2021 and December 31, 2020: As of September 30, 2021 Carrying Amount Fair Value Quoted priced in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets Money market funds $ 37,191 $ 37,191 $ 37,191 $ — $ — Corporate securities 255,428 255,428 — 255,428 — Government securities 31,683 31,683 — 31,683 — Total financial assets $ 324,302 $ 324,302 $ 37,191 $ 287,111 $ — As of December 31, 2020 Carrying Amount Fair Value Quoted Priced in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Financial assets Money market funds $ 240,033 $ 240,033 $ 240,033 $ — $ — Corporate securities 120,008 120,008 — 120,008 — Total financial assets $ 360,041 $ 360,041 $ 240,033 $ 120,008 $ — Cash Equivalents — Cash equivalents of $174,691 as of September 30, 2021 consisted of money market funds of $37,191 and corporate debt securities of $137,500. Cash equivalents of $360,041 as of December 31, 2020 consisted of money market funds of $240,033 and corporate debt securities of $120,008. Money market funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, whereas corporate debt securities are classified within level 2 of the fair value hierarchy because they are valued using inputs other than quoted prices that are observable for the asset or liability either directly or indirectly. Marketable Securities — Marketable securities of $149,611 as of September 30, 2021 consisted of corporate debt securities of $117,928 and government debt securities of $31,683. There were $131,010 current marketable securities and $18,601 noncurrent marketable securities as of September 30, 2021. There were no marketable securities as of December 31, 2020.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, Net September 30, 2021 December 31, 2020 Machinery & equipment $ 2,261 $ 1,989 Computers 8 8 Furniture & fixtures 9 9 Leasehold improvements 161 73 Assets not placed in service 746 51 Total property and equipment 3,185 2,130 Less: Accumulated depreciation (1,791 ) (1,561 ) Property and equipment, net $ 1,394 $ 569 Depreciation expense for the three months ended September 30, 2021 and 2020 was $80 and $75, respectively. Depreciation expense for the nine months ended September 30, 2021 and 2020 was $230 and $257, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consist of the following: September 30, 2021 December 31, 2020 Accrued compensation $ 2,882 $ 3,109 Accrued legal and professional services 214 — Accrued research and development costs 3,554 1,595 Other accrued liabilities 90 99 Total $ 6,740 $ 4,803

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Operating Leases In June 2015, the Company executed a noncancelable operating lease for approximately 13,000 square feet of laboratory, research and development, and office space in Cranbury, New Jersey for an initial base rent of $20.00 per square foot. This location operates as the Company’s current headquarters. In June 2017, the Company obtained an additional noncancelable operating lease for about 6,000 square feet of laboratory space in the same corporate center at an initial rental rate at $22.00 per square foot. As a result of the additional space, both leases will expire June 2022, with an option to renew for an additional five-year In August 2018, the Company executed two noncancelable operating leases. One lease for approximately 6,000 square feet for vivarium, laboratory and general office space in South Brunswick, New Jersey. The initial annual base rent is $15.50 per square foot and a management fee of 3% of the base rent. The Company is obligated to pay, on a pro-rata basis, insurance premiums, real estate taxes and operating costs related to the premises. The lease expires in July 2022, with an option for additional five-year three-year In 2018, the company received a lease incentive for the buildout of 420 Bedford Street in Lexington, MA. The Company was given an allowance for $165 on behalf of the lessor for construction of office space. Management recognizes this allowance as a lease incentive in its Right-of-Use asset and straight-lines the allowance throughout the term of the lease. As of September 30, 2021, the remaining rent incentive pertaining to the Lexington, MA lease totaled $73. In January 2021, the Company signed a lease for 50,581 square feet of office and laboratory space at One Research Way in Princeton, New Jersey. The Company intends to complete the relocation of their headquarters from Cranbury, NJ to One Research Way in Princeton NJ in early 2022. That lease term extends through 2032, has a five-year from the lessor for a buildout of laboratory, vivarium, and office space , to be reimbursed to the C ompany in 2021 and 2022 . Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement. As of September 30 , 2021, no reimbursements were received. The components of lease cost for the three and nine months ended September 30, 2021 are as follows: (in thousands) Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Operating lease cost $ 511 $ 1,180 Variable lease cost 158 470 Total lease cost $ 669 $ 1,650 Amounts reported in the balance sheet for leases where the Company is the lessee as of September 30, 2021 were as follows, in thousands: Operating Leases: Nine Months Ended September 30, 2021 Right-of-use assets, operating leases $ 10,410 Operating lease liabilities, current $ 545 Operating lease liabilities, non-current 10,667 Total operating lease liabilities $ 11,212 Weighted-average remaining lease term (years) 10.12 Weighted-average discount rate 5.75 % Other information related to leases for the nine months ended September 30, 2021 is as follows, in thousands: Cash paid for amounts included in the measurement of lease liabilities $ 535 Leased assets obtained in exchange for new operating lease liabilities 10,314 Future minimum lease payments, net of reimbursements, remaining as of September 30, 2021 under operating leases by fiscal year were as follows, in thousands: Fiscal year 2021 $ (264 ) 2022 (2,164 ) 2023 1,833 2024 1,814 2025 1,869 Thereafter 13,402 Total minimum lease payments $ 16,490 Less: Amounts representing imputed interest (5,278 ) Present value of lease liabilities $ 11,212 Rent expense recorded during the three months ended September 30, 2021 and 2020 was $511 and $118, respectively. Rent expense recorded during the nine months ended September 30, 2021 and 2020 was $1,180 and $444, respectively. The company currently subleases the office space at 420 Bedford Street in Lexington, MA to another company. Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated. Commitments At September 30, 2021, there were no purchase commitments with third-party suppliers.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity The Company is authorized to issue up to 1,000,000,000 shares of common stock with a par value of $0.00001 per share and 5,000,000 shares of preferred stock with a par value of $0.00001 per share. At September 30, 2021 and December 31, 2020, there were 45,352,207 and 44,777,818 shares of common stock issued and outstanding, respectively, and no shares of preferred stock issued and outstanding. Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders. As of September 30, 2021, no dividends on common stock had been declared by the Company.

Stock Plan

Stock Plan	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Plan	8. Stock Plan 2020 Equity Incentive Plan The 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the board of directors on September 24, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan is 4,406,374, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) 4,406,374 shares of common stock, (ii) five percent , or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31. 2020 Employee Stock Purchase Plan The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the board of directors on September 24, 2020. A total of 400,572 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) 801,504 shares of common stock, (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year. For 2021, the 2020 ESPP reserved shares were increased under clause (ii) by 447,778 shares, effective as of January 1, 2021. On May 20, 2021, employees exercised their right to purchase 36,586 shares under the 2020 ESPP. As of September 30, 2021, 36,586 shares are issued or outstanding, and there were 811,944 shares available for issuance, under the 2020 ESPP. 2013 Equity Incentive Plan In 2013, the Company adopted the 2013 Stock Plan (the “2013 Plan”). On September 24, 2020, this plan was replaced by the 2020 Plan, and future issuances of incentive instruments will be governed by that plan. Subject to the provisions of the 2020 Plan, the Company had the option to either forfeit or repurchase remaining shares under the 2013 Equity Incentive Plan on or after the registration date. The Company chose to forfeit the remaining shares. S tock-Based Compensation The following table summarizes option activity for the nine-month period ended September 30, 2021: Options Outstanding Weighted- Weighted Average Aggregate Shares Average Remaining Intrinsic Available Number of Exercise Contractual Life Value for Grant Options Price (in years) (in 000s) Balances, December 31, 2020 4,609,725 4,090,970 $ 3.14 7.13 $ 238,792 Options retired under 2013 Equity Plan (237,542 ) — Options granted (715,380 ) 715,380 $ 30.03 Options forfeited / cancelled 43,117 (43,117 ) $ 6.77 Options exercised — (537,803 ) $ 2.17 Balances September 30, 2021 3,699,920 4,225,430 $ 7.78 7.00 $ 94,079 At September 30, 2021 Vested and expected to vest 4,225,430 $ 7.78 7.00 $ 94,079 Exercisable 2,574,442 $ 2.91 5.84 $ 69,247 At September 30, 2021, the total compensation cost related to nonvested awards not yet recognized is $15,952. The weighted-average period over which the nonvested awards is expected to be recognized is 3.2 years. The Company estimated the fair value of the options using the Black-Scholes options valuation model. The fair value of the options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value was estimated using the following assumptions: Nine Months Ended Year Ended September 30, December 31, 2021 2020 Risk-free interest rate 0.35% - 1.22% 0.31% - 1.51% Expected life (in years) 5.50 - 6.43 4.92 - 6.40 Dividend yield 0% 0% Expected volatility 79.00-79.90% 70.70% - 77.60% The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows: Nine Months Ended September 30, 2021 Risk-free interest rate 0.02% Expected life (in years) 0.5 Dividend yield 0% Expected volatility 79.00% Expected Term: The Company uses the simplified method to calculate expected term described in the SEC’s Staff Accounting Bulletin No. 107, which takes into account vesting term and expiration date of the options. Volatility: Volatility is based on an average of the historical volatilities of comparable publicly traded companies for the expected term. Risk Free Interest Rate: The risk-free rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected term of the option. Dividend Yield: The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model. Stock-based compensation expense recorded under ASC 718 related to stock options granted was allocated to research and development and general and administrative expense as follows: For the Three Months Ended For the Nine Months Ended September 30, September 30, September 30, September 30, 2021 2020 2021 2020 Research and development $ 449 $ 288 $ 983 $ 607 General and administrative 1,347 382 2,590 742 Total stock-based compensation $ 1,796 $ 670 $ 3,573 $ 1,349

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes During the three months ended September 30, 2021 and 2020 and the nine months ended September 30, 2021 and 2020, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a taxable position in the near future.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	10. Net Loss per Share The Company’s convertible preferred stock does not participate in losses. The Company excluded all outstanding stock options and restricted stock awards at each period end from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect. For the Three Months Ended For the Nine Months Ended September 30, 2021 September 30, 2020 September 30, 2021 September 30, 2020 Net loss $ (15,011 ) $ (8,764 ) $ (39,487 ) $ (23,986 ) Weighted-average number of shares - basic and diluted 45,295,232 6,022,457 45,052,100 4,045,527 Net loss per share - basic and diluted $ (0.33 ) $ (1.46 ) (0.88 ) (5.93 )

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Parties	11. Related Parties The Company has consulting agreements with two members of its board of directors. The total of consulting fees paid in each of the three months ended September 30, 2021 and 2020 were $29 and $28, respectively. The total of consulting fees paid in each of the nine months ended September 30, 2021 and 2020 were $85 and $84, respectively. In May of 2021, the two members of the board of directors were awarded 5,781 options of company stock each, as per their updated Scientific Advisory Board agreements. There were no amounts owed under the consulting agreements at September 30, 2021 or December 31, 2020. During the fiscal year ended December 31, 2020, an investor provided $65 of financial consulting services to the Company. The Company has paid the entirety of the fees as of December 31, 2020. No amounts were paid or owed to the investors in the nine months ended September 30, 2021.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The condensed balance sheet as of September 30, 2021, the condensed statements of operations and comprehensive loss, and condensed statements of convertible preferred stock and stockholders’ (deficit) equity for the three and nine months ended September 30, 2021 and 2020, and the condensed statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for any interim period are not necessarily indicative of results for the year ending December 31, 202 1 or for any other subsequent interim period . The condensed balance sheet at December 31, 2020 has been derived from our audited financial statements .
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.
Reverse Stock Split	Reverse Stock Split In September 2020, the Company’s board of directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to affect a 5.2651-for-1 reverse stock split of the Company’s common stock and convertible preferred stock, which was effected on September 18, 2020. The par value of the common stock and convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, convertible preferred stock, stock options, and related per share amounts in these unaudited condensed financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.
Cash, Cash Equivalents and Marketable Securities	Cash, Cash Equivalents and Marketable Securities Management considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. As of September 30, 2021, the company’s long-term marketable debt securities have maturity dates no more than 2 years. The Company’s marketable debt securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in stockholders’ deficit. Premiums and discounts on marketable debt securities are amortized into earnings over the life of the security. For the three months ended September 30, 2021 and 2020, the Company recorded $127 and $6 of amortization, respectively. For the nine months ended September 30, 2021 and 2020, the Company recorded $459 and $152 of amortization, respectively. Restricted cash as of September 30, 2021 included a $822 deposit at the Company’s commercial bank underlying a stand-by letter of credit issued in favor of a landlord (See Note 6) and is classified in current assets.
Comprehensive Loss	Comprehensive Loss The Company presents comprehensive loss in a single statement within its financial statements. Other comprehensive loss consists of unrealized gains and losses on marketable securities, net of tax.
Leases	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset’s economic benefits. The Company determines the initial classification and measurement of its operating right-of-use (“ROU”) assets and operating lease liabilities at the lease commencement date, and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The Company’s policy is to not record leases with a lease term of 12 months or less on its balance sheets. The Company’s only existing leases are for office and laboratory space. The ROU asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the statements of operations. Payments due under each lease agreement include fixed and variable payments. Variable payments relate to the Company’s share of the lessor’s operating costs associated with the underlying asset and are recognized when the event on which those payments are assessed occurs. Neither of the Company’s leases contain residual value guarantees. The interest rate implicit in lease agreements is typically not readily determinable, and as such, the Company utilizes the incremental borrowing rate to calculate lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-02, Leases The right-of-use lease liability for operating leases is based on the net present value of future minimum lease payments. Additionally, the right-of-use asset for operating leases is based on the lease liability adjusted for the reclassification of certain balance sheet amounts such as the long term portion of straight line rent liability and deferred lease incentives. The Company adopted the standard effective January 1, 2021 using the modified retrospective transition method. Upon adoption, the Company applied the package of practical expedients that allows an entity to not reassess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases and (iii) initial direct costs for any expired or existing leases. The Company elected the practical expedient not to apply the recognition requirements to short-term leases, defined as a lease that at the commencement date has a lease term of 12 months or less that does not include a purchase option to purchase the underlying asset that the Company is reasonably certain to exercise. Furthermore, the Company has elected the practical expedient to not separate lease and non-lease components by class of underlying asset for its existing leases. As the Company enters into new leases, it will continue to evaluate this accounting policy for any new classes of underlying assets. Upon adoption, the Company recorded ROU assets of $970 and lease liabilities of $1,129. The standard did not have a material impact on the statement of operations or statement of cash flows. In December 2019, the FASB issued ASU 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas, such as requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company adopted this standard as of January 1, 2021. The adoption did not have a material impact on the Company’s financial statements.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and marketable securities. Cash and cash equivalents include a checking account and a money market account held at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company’s marketable debt securities are carried at fair value and include any unrealized gains and losses. Any investments with unrealized losses are considered to be temporarily impaired. The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of the product, competition from substitute products and larger companies, protection of proprietary technology, any future strategic relationships and dependence on key individuals. Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company. In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a “Public Health Emergency of International Concern,” which continues to spread throughout the world . The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. The Company continues to monitor the impact of the COVID-19 outbreak closely. The full extent to which the COVID-19 outbreak will impact its operations or financial results remains uncertain.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values	The Company’s financial assets consist of money market funds, U.S. government debt securities and corporate debt securities. The following tables show the Company’s cash equivalents and available-for-sale securities’ carrying amounts and fair values at September 30, 2021 and December 31, 2020: As of September 30, 2021 Carrying Amount Fair Value Quoted priced in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets Money market funds $ 37,191 $ 37,191 $ 37,191 $ — $ — Corporate securities 255,428 255,428 — 255,428 — Government securities 31,683 31,683 — 31,683 — Total financial assets $ 324,302 $ 324,302 $ 37,191 $ 287,111 $ — As of December 31, 2020 Carrying Amount Fair Value Quoted Priced in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Financial assets Money market funds $ 240,033 $ 240,033 $ 240,033 $ — $ — Corporate securities 120,008 120,008 — 120,008 — Total financial assets $ 360,041 $ 360,041 $ 240,033 $ 120,008 $ —

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	September 30, 2021 December 31, 2020 Machinery & equipment $ 2,261 $ 1,989 Computers 8 8 Furniture & fixtures 9 9 Leasehold improvements 161 73 Assets not placed in service 746 51 Total property and equipment 3,185 2,130 Less: Accumulated depreciation (1,791 ) (1,561 ) Property and equipment, net $ 1,394 $ 569

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consist of the following: September 30, 2021 December 31, 2020 Accrued compensation $ 2,882 $ 3,109 Accrued legal and professional services 214 — Accrued research and development costs 3,554 1,595 Other accrued liabilities 90 99 Total $ 6,740 $ 4,803

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Summary of Components of Lease Cost	The components of lease cost for the three and nine months ended September 30, 2021 are as follows: (in thousands) Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Operating lease cost $ 511 $ 1,180 Variable lease cost 158 470 Total lease cost $ 669 $ 1,650
Schedule of Amounts Reported in Consolidated Balance Sheets for Leases	Amounts reported in the balance sheet for leases where the Company is the lessee as of September 30, 2021 were as follows, in thousands: Operating Leases: Nine Months Ended September 30, 2021 Right-of-use assets, operating leases $ 10,410 Operating lease liabilities, current $ 545 Operating lease liabilities, non-current 10,667 Total operating lease liabilities $ 11,212 Weighted-average remaining lease term (years) 10.12 Weighted-average discount rate 5.75 %
Summary of Other Information Related to Leases	Other information related to leases for the nine months ended September 30, 2021 is as follows, in thousands: Cash paid for amounts included in the measurement of lease liabilities $ 535 Leased assets obtained in exchange for new operating lease liabilities 10,314
Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases	Future minimum lease payments, net of reimbursements, remaining as of September 30, 2021 under operating leases by fiscal year were as follows, in thousands: Fiscal year 2021 $ (264 ) 2022 (2,164 ) 2023 1,833 2024 1,814 2025 1,869 Thereafter 13,402 Total minimum lease payments $ 16,490 Less: Amounts representing imputed interest (5,278 ) Present value of lease liabilities $ 11,212

Stock Plan (Tables)

Stock Plan (Tables)	9 Months Ended
	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Stock Options Activity	The following table summarizes option activity for the nine-month period ended September 30, 2021: Options Outstanding Weighted- Weighted Average Aggregate Shares Average Remaining Intrinsic Available Number of Exercise Contractual Life Value for Grant Options Price (in years) (in 000s) Balances, December 31, 2020 4,609,725 4,090,970 $ 3.14 7.13 $ 238,792 Options retired under 2013 Equity Plan (237,542 ) — Options granted (715,380 ) 715,380 $ 30.03 Options forfeited / cancelled 43,117 (43,117 ) $ 6.77 Options exercised — (537,803 ) $ 2.17 Balances September 30, 2021 3,699,920 4,225,430 $ 7.78 7.00 $ 94,079 At September 30, 2021 Vested and expected to vest 4,225,430 $ 7.78 7.00 $ 94,079 Exercisable 2,574,442 $ 2.91 5.84 $ 69,247
Schedule of Estimated Fair Value of Stock Options	The Company estimated the fair value of the options using the Black-Scholes options valuation model. The fair value of the options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value was estimated using the following assumptions: Nine Months Ended Year Ended September 30, December 31, 2021 2020 Risk-free interest rate 0.35% - 1.22% 0.31% - 1.51% Expected life (in years) 5.50 - 6.43 4.92 - 6.40 Dividend yield 0% 0% Expected volatility 79.00-79.90% 70.70% - 77.60%
Stock-based Compensation Expense Related to Options Granted Recorded and Allocated	Stock-based compensation expense recorded under ASC 718 related to stock options granted was allocated to research and development and general and administrative expense as follows: For the Three Months Ended For the Nine Months Ended September 30, September 30, September 30, September 30, 2021 2020 2021 2020 Research and development $ 449 $ 288 $ 983 $ 607 General and administrative 1,347 382 2,590 742 Total stock-based compensation $ 1,796 $ 670 $ 3,573 $ 1,349
2020 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Estimated Fair Value of Stock Options	The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP are as follows: Nine Months Ended September 30, 2021 Risk-free interest rate 0.02% Expected life (in years) 0.5 Dividend yield 0% Expected volatility 79.00%

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Computation of Net Loss per Share	For the Three Months Ended For the Nine Months Ended September 30, 2021 September 30, 2020 September 30, 2021 September 30, 2020 Net loss $ (15,011 ) $ (8,764 ) $ (39,487 ) $ (23,986 ) Weighted-average number of shares - basic and diluted 45,295,232 6,022,457 45,052,100 4,045,527 Net loss per share - basic and diluted $ (0.33 ) $ (1.46 ) (0.88 ) (5.93 )

Formation and Business of the_2

Formation and Business of the Company - Additional Information (Details)	Sep. 25, 2020USD ($)$ / sharesshares	Sep. 18, 2020	Sep. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)	Sep. 30, 2020USD ($)shares	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Organization Consolidation And Presentation [Line Items]
Proceeds from issuance of common stock, gross	$ 243,536
Proceeds from issuance of common stock, net	$ 223,161									$ 224,541,000
Reverse stock split description									5.2651-for-1 reverse stock split of the Company’s common stock and convertible preferred stock
Reverse stock split conversion ratio		5.2651
Net loss			$ (15,011,000)	$ (12,874,000)	$ (11,602,000)	$ (8,764,000)	$ (7,967,000)	$ (7,255,000)	$ (39,487,000)	(23,986,000)
Cash used in operating activities									(34,543,000)	$ (22,427,000)
Accumulated deficit			(149,367,000)						(149,367,000)		$ (109,880,000)
Cash, cash equivalents and restricted cash			177,463,000						177,463,000
Short and long term marketable securities			$ 149,611,000						$ 149,611,000		$ 0
Common Stock
Organization Consolidation And Presentation [Line Items]
Number of shares sold | shares						13,529,750
Conversion of convertible preferred stock to common stock, Shares | shares						28,188,110
Convertible Preferred Stock | Common Stock
Organization Consolidation And Presentation [Line Items]
Reverse stock split description									5.2651-for-1 reverse stock split of its issued and outstanding common and convertible preferred stock
IPO | Common Stock
Organization Consolidation And Presentation [Line Items]
Number of shares sold | shares	13,529,750
Public offering price per share | $ / shares	$ 18
IPO | Convertible Preferred Stock | Common Stock
Organization Consolidation And Presentation [Line Items]
Conversion of convertible preferred stock to common stock, Shares | shares	28,188,110
Underwriters | Common Stock
Organization Consolidation And Presentation [Line Items]
Option to purchase common stock | shares	1,764,750

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	Sep. 18, 2020	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Jan. 01, 2021USD ($)
Summary Of Significant Accounting Policie [Line Items]
Reverse stock split description				5.2651-for-1 reverse stock split of the Company’s common stock and convertible preferred stock
Reverse stock split conversion ratio	5.2651
Amortization of available-for-sale debt securities		$ 127	$ 6	$ 459	$ 152
Restricted cash		822		822
ROU assets		10,410		10,410
Lease liabilities		$ 11,212		$ 11,212
ASU 2016-02
Summary Of Significant Accounting Policie [Line Items]
Adoption of accounting standards update [true false]		true		true
Accounting standards update, adoption date		Jan. 1, 2021		Jan. 1, 2021
ROU assets						$ 970
Lease liabilities						$ 1,129
ASU 2019-12
Summary Of Significant Accounting Policie [Line Items]
Adoption of accounting standards update [true false]		true		true
Accounting standards update, adoption date		Jan. 1, 2021		Jan. 1, 2021
Accounting standards update, immaterial effect [true false]		true		true

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Cash Equivalents and Available-for-sale Securities Carrying Amounts and Fair Values (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Quoted Priced in Active Markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 37,191	$ 240,033
Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	287,111	120,008
Corporate Securities | Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	255,428	120,008
Government Securities | Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	31,683
Money Market Funds | Quoted Priced in Active Markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	37,191	240,033
Carrying Amount
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	324,302	360,041
Carrying Amount | Corporate Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	255,428	120,008
Carrying Amount | Government Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	31,683
Carrying Amount | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	37,191	240,033
Carrying Amount
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	324,302	360,041
Carrying Amount | Corporate Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	255,428	120,008
Carrying Amount | Government Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	31,683
Carrying Amount | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 37,191	$ 240,033

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	$ 174,691,000	$ 360,041,000
Marketable Securities	149,611,000	0
Marketable securities noncurrent	18,601,000
Marketable securities current	131,010,000
Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	117,928,000
Corporate Debt Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	137,500,000	120,008,000
Government Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	31,683,000
Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	$ 37,191,000	$ 240,033,000

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Total property and equipment	$ 3,185	$ 2,130
Less: Accumulated depreciation	(1,791)	(1,561)
Property and equipment, net	1,394	569
Machinery & Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	2,261	1,989
Computers
Property Plant And Equipment [Line Items]
Total property and equipment	8	8
Furniture & Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	9	9
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	161	73
Assets Not Placed in Service
Property Plant And Equipment [Line Items]
Total property and equipment	$ 746	$ 51

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Depreciation	$ 80	$ 75	$ 230	$ 257

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued compensation	$ 2,882	$ 3,109
Accrued legal and professional services	214
Accrued research and development costs	3,554	1,595
Other accrued liabilities	90	99
Total	$ 6,740	$ 4,803

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	1 Months Ended			3 Months Ended			9 Months Ended		12 Months Ended
	Apr. 30, 2021	Jan. 31, 2021USD ($)ft²	Aug. 31, 2018ft²Lease$ / ft²	Sep. 30, 2021USD ($)$ / ft²	Mar. 31, 2021	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / ft²	Sep. 30, 2020USD ($)	Dec. 31, 2018USD ($)	Jun. 30, 2017ft²$ / ft²	Jun. 30, 2015ft²$ / ft²
Commitments And Contingencies Disclosure [Line Items]
Number of noncancelable operating leases | Lease			2
Operating lease, payments							$ 535,000
Rent expense				$ 511,000		$ 118,000	1,180,000	$ 444,000
Purchase commitments				$ 0			$ 0
Cranbury, New Jersey
Commitments And Contingencies Disclosure [Line Items]
Area of operating lease property | ft²										6,000	13,000
Initial base rent per square foot | $ / ft²										22	20
Operating lease expiration period							2022-06
Operating lease, renewal term				5 years			5 years
Operating lease maintenance expense per square foot | $ / ft²				3			3
Operating lease, description							Both leases include a common area maintenance expense for $3.00 per square foot with an increase of 3% on the first month of each calendar year during the lease term and a management fee of 3% of the base rent.
Management fee of base rent percentage				3.00%			3.00%
South Brunswick, New Jersey.
Commitments And Contingencies Disclosure [Line Items]
Area of operating lease property | ft²			6,000
Initial base rent per square foot | $ / ft²			15.50
Operating lease expiration period			2022-07
Operating lease, renewal term			5 years
Management fee of base rent percentage			3.00%
Lexington, Massachusetts
Commitments And Contingencies Disclosure [Line Items]
Initial base rent per square foot | $ / ft²			28.50
Operating lease expiration period			2023-08
Operating lease, renewal term			3 years
Initial base rent increased per square foot | $ / ft²			1
Allowance on behalf of lessor for construction of office space.									$ 165,000
Remaining rent incentives				$ 73,000			$ 73,000
Sublease expiration period							2023-08
Princeton, New Jersey
Commitments And Contingencies Disclosure [Line Items]
Operating lease, description					That lease term extends through 2032, has a five-year extension option, and is intended to replace our two existing facilities and the space is expected to become the Company’s future headquarters
Lease area of square feet | ft²		50,581
Operating Leases, extended year		2032
Operating leases, extension period		5 years
Operating lease, payments		$ 19,600,000
Operating leases extended month and year		2032-05
Tenant improvement allowance		$ 4,100,000
Reimbursements received				0			$ 0
Sublease with tenant office space starting period	2021-04
Sublease with tenant office space ending period	2021-07
Sublease income				$ 29,000			$ 89,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Components of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Leases [Abstract]
Operating lease cost	$ 511	$ 1,180
Variable lease cost	158	470
Total lease cost	$ 669	$ 1,650

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Amounts Reported in Consolidated Balance Sheets for Leases (Details) $ in Thousands	Sep. 30, 2021USD ($)
Operating Leases:
Right-of-use assets, operating leases	$ 10,410
Operating lease liabilities, current	545
Operating lease liabilities, non-current	10,667
Total operating lease liabilities	$ 11,212
Weighted-average remaining lease term (years)	10 years 1 month 13 days
Weighted-average discount rate	5.75%

Commitments and Contingencies_4

Commitments and Contingencies - Summary of Other Information Related to Leases (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 535
Leased assets obtained in exchange for new operating lease liabilities	$ 10,314

Commitments and Contingencies_5

Commitments and Contingencies - Schedule of Minimum Lease Payments, Net of Reimbursements, under Operating Leases (Details) $ in Thousands	Sep. 30, 2021USD ($)
Commitments And Contingencies Disclosure [Abstract]
2021	$ (264)
2022	(2,164)
2023	1,833
2024	1,814
2025	1,869
Thereafter	13,402
Total minimum lease payments	16,490
Less: Amounts representing imputed interest	(5,278)
Present value of lease liabilities	$ 11,212

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares issued	45,352,207	44,777,818
Common stock, shares outstanding	45,352,207	44,777,818
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Dividends, common stock declared	$ 0

Stock Plan - Additional Informa

Stock Plan - Additional Information (Details) - USD ($) $ in Thousands	May 20, 2021	Sep. 30, 2021	Dec. 31, 2020	Jan. 01, 2021	Sep. 24, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation cost related to nonvested awards not yet recognized		$ 15,952
Weighted-average period over nonvested awards expected to be recognized		3 years 2 months 12 days
Dividend yield		0.00%	0.00%
2020 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance					4,406,374
Number of additional shares reserved for issuance, minimum					4,406,374
Percentage of number of shares of common stock outstanding increase					5.00%
Number of additional shares reserved for issuance, maximum				1,343,334
Shares issued		3,699,920
2020 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance		811,944		447,778	400,572
Percentage of number of shares of common stock outstanding increase					1.00%
Number of additional shares reserved for issuance, maximum					801,504
Shares issued		36,586
Employees exercised their right to purchase shares	36,586
Shares outstanding		36,586
Dividend yield		0.00%

Stock Plan - Schedule of Stock

Stock Plan - Schedule of Stock Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Shares Available For Grant
Shares Available for Grant, Balance	4,609,725
Shares Available for Grant, Options granted	(715,380)
Shares Available for Grant, Options forfeited / cancelled	43,117
Shares Available for Grant, Balance	3,699,920	4,609,725
Number of Options
Options	4,090,970
Options granted, Number of Options	715,380
Options forfeited / cancelled, Number of Options	(43,117)
Options exercised, Number of Options	(537,803)
Options Outstanding, Number of Options	4,225,430	4,090,970
Vested and expected to vest, Number of Options	4,225,430
Exercisable, Number of Options	2,574,442
Weighted Average Exercise Price
Options Outstanding, Weighted Average Exercise Price	$ 3.14
Options granted, Weighted Average Exercise Price	30.03
Options forfeited / cancelled, Weighted Average Exercise Price	6.77
Options exercised, Weighted Average Exercise Price	2.17
Options Outstanding, Weighted Average Exercise Price	7.78	$ 3.14
Vested and expected to vest, Weighted Average Exercise Price	7.78
Exercisable, Weighted Average Exercise Price	$ 2.91
Weighted-Average Remaining Contractual Life
Options Outstanding, Weighted-Average Remaining Contractual Life	7 years	7 years 1 month 17 days
Vested and expected to vest, Weighted-Average Remaining Contractual Life	7 years
Exercisable, Weighted-Average Remaining Contractual Life	5 years 10 months 2 days
Aggregate Intrinsic Value
Options Outstanding, Aggregate Intrinsic Value	$ 94,079	$ 238,792
Vested and expected to vest, Aggregate Intrinsic Value	94,079
Exercisable, Aggregate Intrinsic Value	$ 69,247
2013 Stock Plan
Shares Available For Grant
Shares Available for Grant, Options retired	(237,542)

Stock Plan - Schedule of Estima

Stock Plan - Schedule of Estimated Fair Value of Stock Options (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.35%	0.31%
Risk-free interest rate, maximum	1.22%	1.51%
Dividend yield	0.00%	0.00%
Expected volatility, minimum	79.00%	70.70%
Expected volatility, maximum	79.90%	77.60%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)	5 years 6 months	4 years 11 months 1 day
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)	6 years 5 months 4 days	6 years 4 months 24 days

Stock Plan - Summary of Weighte

Stock Plan - Summary of Weighted Average Assumptions Used to Estimate Fair Value of Stock Purchase Rights Under ESPP (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
2020 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.02%
Expected life (in years)	6 months
Dividend yield	0.00%
Expected volatility	79.00%

Stock Plan - Stock-based Compen

Stock Plan - Stock-based Compensation Expense Related to Options Granted Recorded and Allocated (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 1,796	$ 670	$ 3,573	$ 1,349
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	449	288	983	607
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 1,347	$ 382	$ 2,590	$ 742

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Computation of Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net loss	$ (15,011)	$ (12,874)	$ (11,602)	$ (8,764)	$ (7,967)	$ (7,255)	$ (39,487)	$ (23,986)
Weighted-average number of shares - basic and diluted	45,295,232			6,022,457			45,052,100	4,045,527
Net loss per share -- basic and diluted	$ (0.33)			$ (1.46)			$ (0.88)	$ (5.93)

Related Parties - Additional In

Related Parties - Additional Information (Details)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2021Membershares	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)Membershares	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Related Party Transaction [Line Items]
Options awarded | shares				715,380
Board of Directors
Related Party Transaction [Line Items]
Number of consulting agreement members | Member	2			2
Consulting fees		$ 29,000	$ 28,000	$ 85,000	$ 84,000
Amount owed to related party		0		0		$ 0
Options awarded | shares	5,781
Investor
Related Party Transaction [Line Items]
Consulting fees						$ 65,000
Amount owed to related party		0		0
Amount paid to related party		$ 0		$ 0